For treatment of HR+, HER2– recurrent or metastatic breast cancer (MBC) in postmenopausal women or premenopausal women receiving ovarian ablation or suppression
National Comprehensive Cancer Network® (NCCN®) recommends abemaciclib (Verzenio®) as a treatment option in combination with fulvestrant or an AI and as a single agent1
Abemaciclib plus an aromatase inhibitor (AI)
Abemaciclib plus fulvestrant
Second and subsequent lines of therapy
Abemaciclib plus fulvestrant if CDK4 & 6 inhibitor not previously used†
- Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer V.8.2021. ©National Comprehensive Cancer Network, Inc. 2021. All rights reserved. Accessed September 13, 2021. To view the most recent and complete version of the guideline, go online to NCCN.org.